Patents by Inventor David Lonard

David Lonard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9683237
    Abstract: The present invention includes compositions and methods for making and using a RNAi capable of reducing expression of two or more genes, comprising: a first RNAi molecule that reduces the expression of a first target gene; a second RNAi molecule that reduces the expression of the first or a second target gene; and optionally a third RNAi molecule that reduces the expression of the first, the second, or a third target gene, wherein the RNAi molecules reduce the expression level of, e.g., mutated KRAS, SRC-3, EGFR, PIK3, NCOA3, or ERalpha1, and can be, e.g., miRNAs, shRNAs, or bifunctional shRNAs.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: June 20, 2017
    Assignees: STRIKE BIO, INC., BAYLOR COLLEGE OF MEDICINE
    Inventors: Donald Rao, John Nemunaitis, Bert W. O'Malley, David Lonard
  • Publication number: 20150307885
    Abstract: The present invention includes compositions and methods for making and using a RNAi capable of reducing expression of two or more genes, comprising: a first RNAi molecule that reduces the expression of a first target gene; a second RNAi molecule that reduces the expression of the first or a second target gene; and optionally a third RNAi molecule that reduces the expression of the first, the second, or a third target gene, wherein the RNAi molecules reduce the expression level of, e.g., mutated KRAS, SRC-3, EGFR, PIK3, NCOA3, or ERalpha1, and can be, e.g., miRNAs, shRNAs, or bifunctional shRNAs.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 29, 2015
    Inventors: Donald Rao, John Nemunaitis, Bert W. O'Malley, David Lonard
  • Publication number: 20130266639
    Abstract: The present invention includes compositions and methods treating triple negative breast cancer comprising administering a therapeutically effective amount of a formulation that includes vector that expresses an SRC-1-specific bifunctional shRNA, an SRC-3-specific bifunctional shRNA, or both, to impair triple negative breast cancer cell growth.
    Type: Application
    Filed: June 13, 2013
    Publication date: October 10, 2013
    Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer, Bert W. O'Malley, David Lonard
  • Publication number: 20130259925
    Abstract: The present invention includes compositions and methods of making and using an expression vector comprising a promoter and a nucleic acid insert operably linked to the promoter, wherein the insert encodes one or more short hairpin RNAs (shRNA) capable of inhibiting an expression of a SRC-3 gene via RNA interference, wherein the one or more shRNA comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the SRC-3.
    Type: Application
    Filed: March 27, 2013
    Publication date: October 3, 2013
    Applicants: BAYLOR COLLEGE OF MEDICINE, GRADALIS, INC.
    Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer, Bert W. O'Malley, David Lonard